The European Commission (EC) approved the acquisition of specialty and branded generics unit of Abbot Laboratories' non-U. S. Developed Markets Specialty and Branded Generics Business (Abbott EPD-DM). This Swiss-based division of Abbott distributes branded ex-originator products with expired patents, which include a women’s health portfolio. EC demanded that Mylan divest marketing authorizations and contracts for certain products in several European markets in order to maintain adequate competition. The deal with Abbott is conditional on meeting these requirements. Mylan also announced that it is acquiring women’s health business from the Indian company Famy Care. This deal will further augment Mylan’s presence in women’s health.
Mylan Rx product sales reached $7.6 bln in 2014 placing it above Daiichi Sankyo, Otsuka Holdings, UCB and Vertex Pharmaceuticals in the rating of pharmaceutical companies by sales volume.

Sources: GaBI Online — Generics and Biosimilars Initiative, Reuters, EvaluatePharma®